Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    flydubai adds Aktau, Atyrau and Tyumen to winter network

    November 21, 2026

    UK and EU agree digital partnership at Brussels summit

    November 21, 2026

    Russian researchers develop heat resistant alloy for flights

    November 20, 2026
    Irish MonitorIrish Monitor
    • Automotive

      Austria electric car registrations jump 63% in October

      November 14, 2026

      Jaguar Type 01 electric GT debuts with 1,030 PS

      October 7, 2026

      German automaker Porsche extends site guarantees until 2035

      July 28, 2026

      FIA renews push for V8 engines in Formula 1

      July 4, 2026

      Electric car discounts narrow in German market

      May 30, 2026
    • Business

      Euro area annual inflation rises in October as energy jumps

      November 20, 2026

      European gas prices fall 4% to $998 per 1,000 cubic metres

      November 18, 2026

      Gold hovers near one-year low as firm dollar weighs

      November 18, 2026

      Russia’s IT small business sector grows 15% to 256,000 firms

      November 17, 2026

      Italy fines Meta €805 million over Facebook photo access

      November 16, 2026
    • Entertainment

      Generative AI in entertainment advances beyond Affleck’s view

      January 27, 2026

      Apple Arcade adds Jeopardy and NFL games in September update

      August 19, 2025

      Disney and Marvel’s R-rated film hits billion-dollar milestone

      August 17, 2024

      Web3 leader Immutable rolls out $50M gaming rewards initiative

      April 27, 2024

      USHER’s pre-Super Bowl experience on Apple Music

      February 7, 2024
    • Health

      WHO says ending cholera by 2030 is within reach

      November 12, 2026

      Global Impact of 2026 Nobel Medicine Award Highlights Optogenetics Breakthrough

      October 6, 2026

      Global Study from UAE Links Environment and Lifestyle to Accelerated Biological Aging

      October 3, 2026

      WHO Issues Global Heat Risk Guidelines for Mass Gatherings to Safeguard Public Health

      October 2, 2026

      Natural Compound from Pomegranates Shows Promise for Heart Health in UK Research

      October 1, 2026
    • Lifestyle

      Adidas launches You Got This campaign on sideline support

      March 3, 2026

      JP Morgan funds Fresha with $31 million for AI and robotics growth

      August 23, 2024

      Adidas, Highsnobiety debut limited-edition sneakers

      January 6, 2024

      Unraveling Starbucks’ phenomenon as a worldwide coffee powerhouse

      September 1, 2023

      How Nike’s Kobe 8 Protro Halo Marks an Emotional Milestone

      August 29, 2023
    • Luxury

      Price hikes and lack of innovation erode luxury market confidence

      November 18, 2024

      Uncover the allure of Rolex Deepsea – luxury awaits.

      April 10, 2024

      Beyond timekeeping to the prestige of the Rolex Day-Date

      March 2, 2024

      Rare uncut emerald dazzles at Sharjah show

      February 1, 2024

      Porsche and Frauscher launch the electric 850 Fantom Air

      October 17, 2023
    • News

      UK and EU agree digital partnership at Brussels summit

      November 21, 2026

      European Commission confirms AI-driven cyberattack

      November 20, 2026

      EU tells Andy Burnham no deals unless UK joins single market

      November 19, 2026

      Milburn review seeks reset to get 440,000 young people into work

      November 17, 2026

      EU and Nigeria sign agreement to speed up migrant returns

      November 12, 2026
    • Sports

      IOC and CAS rulings open path for Russia’s sporting return

      November 9, 2026

      Spain knock Portugal out of FIFA World Cup

      July 7, 2026

      Haaland double sends Norway past Brazil in World Cup

      July 6, 2026

      Egypt advance after shootout win over Australia

      July 4, 2026

      Spain advances after 3-0 World Cup win over Austria

      July 3, 2026
    • Technology

      Russian researchers develop heat resistant alloy for flights

      November 20, 2026

      EU launches €525 million platform for chip design start-ups

      November 6, 2026

      Putin allows temporary use of foreign data centres

      November 3, 2026

      Apple iPhone Duo redefines foldables with passport design

      November 2, 2026

      Apple brings OLED and Touch to new MacBook Pro

      October 29, 2026
    • Travel

      flydubai adds Aktau, Atyrau and Tyumen to winter network

      November 21, 2026

      flydubai adds winter flights to Riga, Salzburg and Vilnius

      November 11, 2026

      European Union Sees 1.321 Billion Tourist Nights in Early 2026 Period

      September 3, 2026

      Russia’s International Tourism Gains Momentum Across Major Regions in Early 2026

      September 2, 2026

      Shropshire Extends Free Weekday Bus Travel to Disabled Pass Holders Across the Entire Region

      August 22, 2026
    Irish MonitorIrish Monitor
    Home » FDA grants approval to Cobenfy for schizophrenia management
    Health

    FDA grants approval to Cobenfy for schizophrenia management

    September 29, 2024
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    MENA Newswire News Desk: The U.S. Food and Drug Administration (FDA) has approved Cobenfy, a new medication for the treatment of schizophrenia, marking the first major advance in this area in more than three decades. Cobenfy, developed by Bristol Myers Squibb, is a twice-daily oral medication that combines two drugs, xanomeline and trospium chloride, offering a new therapeutic option for managing schizophrenia symptoms like hallucinations, delusions, and disorganized thinking.

    FDA grants approval to Cobenfy for schizophrenia management

    The FDA’s approval of Cobenfy offers fresh hope for millions of people living with schizophrenia, a severe mental health disorder that affects approximately 24 million people globally. According to Dr. Tiffany Farchione, Director of the Division of Psychiatry at the FDA’s Center for Drug Evaluation and Research, the approval breaks new ground in the treatment of this condition. “This is the first new approach to treating schizophrenia in decades, offering a valuable alternative to the antipsychotic medications that have been standard for so long,” she said.

    Most existing schizophrenia treatments focus on altering dopamine levels in the brain, a neurotransmitter linked to mood and behavior. Cobenfy, however, targets acetylcholine receptors, a different pathway in the brain that influences memory, learning, and attention. This novel mechanism of action is particularly important for patients who experience side effects such as weight gain, drowsiness, or movement disorders from traditional antipsychotics.

    In clinical trials, Cobenfy demonstrated significant effectiveness in reducing schizophrenia symptoms, with only 6% of patients discontinuing the drug due to side effects, compared to 20-30% with older medications. Dr. Samit Hirawat, Chief Medical Officer at Bristol Myers Squibb, hailed the results as a major improvement over previous treatment options.

    Common side effects of Cobenfy include nausea, constipation, and increased heart rate, according to the FDA’s approval notice. However, these side effects were notably less severe than those caused by earlier medications. Dr. Leslie Citrome, a professor of psychiatry at New York Medical College, emphasized that the drug could benefit patients who cannot tolerate the side effects of current treatments.

    Schizophrenia is a lifelong mental illness that typically begins in late adolescence or early adulthood and is characterized by distorted thinking, behavior, and emotions. It often leads to significant challenges in daily functioning, impacting work and relationships. The approval of Cobenfy could represent a breakthrough for patients who have struggled with available treatments for years. Cobenfy is expected to be available for prescription by the end of October, according to Adam Lenkowsky, Executive Vice President at Bristol Myers Squibb. Ongoing studies are also exploring its potential for treating other conditions, including Alzheimer’s disease and bipolar disorder.

    Related Posts

    Austria electric car registrations jump 63% in October

    November 14, 2026

    WHO says ending cholera by 2030 is within reach

    November 12, 2026

    IOC and CAS rulings open path for Russia’s sporting return

    November 9, 2026

    MENA Newswire Expands Network with Eurasian Newswire

    October 15, 2026

    Global Impact of 2026 Nobel Medicine Award Highlights Optogenetics Breakthrough

    October 6, 2026

    Global Study from UAE Links Environment and Lifestyle to Accelerated Biological Aging

    October 3, 2026
    Editor's Pick

    flydubai adds Aktau, Atyrau and Tyumen to winter network

    November 21, 2026

    UK and EU agree digital partnership at Brussels summit

    November 21, 2026

    Russian researchers develop heat resistant alloy for flights

    November 20, 2026

    European Commission confirms AI-driven cyberattack

    November 20, 2026

    Euro area annual inflation rises in October as energy jumps

    November 20, 2026

    EU tells Andy Burnham no deals unless UK joins single market

    November 19, 2026

    European gas prices fall 4% to $998 per 1,000 cubic metres

    November 18, 2026

    Gold hovers near one-year low as firm dollar weighs

    November 18, 2026
    © 2024 Irish Monitor | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.